Chapter 122. Dermatomyositis

  1. Robert P. Lisak MD, FAAN, FRCP Parker Webber Chair Professor Chair Neurologist-in-Chief Chief3,4,
  2. Daniel D. Truong MD, FAAN Head5,
  3. William M. Carroll MBBS, MD, FRACP, FRCP(E) Head6 and
  4. Roongroj Bhidayasiri MD, FRCP Director7,8
  1. Marinos C. Dalakas MD Chair Professor Chief1,2

Published Online: 18 MAY 2010

DOI: 10.1002/9781444317008.ch122

International Neurology: A Clinical Approach

International Neurology: A Clinical Approach

How to Cite

Dalakas, M. C. (2009) Dermatomyositis, in International Neurology: A Clinical Approach (eds R. P. Lisak, D. D. Truong, W. M. Carroll and R. Bhidayasiri), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444317008.ch122

Editor Information

  1. 3

    Wayne State University School of Medicine, Detroit, MI, USA

  2. 4

    Detroit Medical Center, Harper University Hospital, Detroit, MI, USA

  3. 5

    The Parkinson and Movement Disorder Institute, Memorial Neuroscience Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA

  4. 6

    Sir Charles Gairdner Hospital, Nedlands, Perth, Australia

  5. 7

    Chulalongkorn Comprehensive Movement Disorders Center, Chulalongkorn University Hospital, Bangkok, Thailand

  6. 8

    University of California at Los Angeles, School of Medicine, Los Angeles, CA, USA

Author Information

  1. 1

    Imperial College, London, UK

  2. 2

    Thomas Jefferson University, Philadelphia, USA

Publication History

  1. Published Online: 18 MAY 2010
  2. Published Print: 11 SEP 2009

ISBN Information

Print ISBN: 9781405157384

Online ISBN: 9781444317008

SEARCH

Keywords:

  • dermatomyositis (DM), one of three main inflammatory myopathies;
  • polymyositis (PM) and inclusion-body myositis (IBM);
  • DM in children and adults - distinct clinical entity because of characteristic rash accompanying or preceding muscle weakness;
  • DM occurring alone, overlapping with scleroderma and mixed connective tissue disease;
  • imunopathogenesis - evidence of humorally mediated process based on immunopathologic studies;
  • DM diagnosis, easy because of characteristic skin changes appearing unique for DM;
  • disease treated with immunosuppressive or immunomodulating agents;
  • natural history of DM - unknown, and patients treated with steroids

Summary

This chapter contains sections titled:

  • Introduction

  • Clinical manifestations

  • Imunopathogenesis

  • Diagnosis

  • Treatment

  • Prognosis and complications

  • Further reading